KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $61.6 million.

  • Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) fell 874.67% to $61.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.6 million, marking a year-over-year decrease of 874.67%. This contributed to the annual value of $66.0 million for FY2024, which is 840.76% down from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) is $61.6 million, which was down 874.67% from $61.2 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $73.8 million for Q1 2023, and its period low was $58.4 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $65.1 million, with a median of $63.1 million in 2022.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) surged by 1726.99% in 2023 and then plummeted by 1522.82% in 2024.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $59.7 million in 2021, then rose by 4.77% to $62.5 million in 2022, then increased by 15.23% to $72.1 million in 2023, then fell by 8.41% to $66.0 million in 2024, then dropped by 6.67% to $61.6 million in 2025.
  • Its last three reported values are $61.6 million in Q3 2025, $61.2 million for Q2 2025, and $66.0 million during Q4 2024.